Assessment of Systemic Immune Inflammation Index to Predict SARS-CoV-2 Infection

Dea Noviana Pramantik, Dwi Aryani

Abstract


Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and has become a major health problem worldwide. Inflammation plays a vital role in the pathophysiology of COVID-19. Systemic Immune Inflammation Index (SII) is an index obtained from calculating the platelets counts, neutrophils, and lymphocytes, which can indicate the inflammation status and immunity. This study aimed to determine the potential of SII as a predictor of SARS-CoV-2 infection in suspected COVID-19 subjects. A retrospective study was carried out by obtaining medical record data in June 2020 at Sleman General Hospital. An unpaired T-test or the Mann-Whitney test was used to determine the statistical difference. A Receiver Operating Characteristic (ROC) curve was generated and used to get the cut-off values. Bivariate analysis was performed using Chi-Square. There were 84 subjects consisting of 46 (54.8%) males and 38 (45.2%) females with a mean age of 42.4±16.356 years. There was a significant difference in the neutrophils count (p=0.045), monocytes (p=0.001), and eosinophils (p=0.037) between subjects with positive and negative SARS-CoV-2 PCR. The median SII in the positive and negative SARS-CoV-2 PCR group was 780.12 (301.21-2178.90)x103/µL and 584.14 (117.79-1933.87)x103/µL (p=0.045), respectively. Bivariate analysis showed significant results at SII > 705 x103/µL in suspected COVID-19 patients to obtain a positive SARS-CoV-2 PCR result with Odds Ratio (OR) of 4.00 (95% CI 1.580-10.127), p=0.003. Patients with suspected SARS-CoV-2 infection with high SII levels had a greater risk of a positive SARS-CoV-2 in PCR test

Keywords


COVID-19, SARS-CoV-2, systemic immune inflammation index

Full Text:

PDF

References


Kementerian Kesehatan RI. Pedoman pencegahan

dan pengendalian Coronavirus Disesase (COVID-19).

Jakarta, Kemenkes, 2020; 17-24.

World Health Organization. WHO COVID-19

preparedness and response progress report February

to June 30, 2020. Geneva, WHO, 2020; 5-6.

Chen G, Wu D, Guo W, Cao Y, Huang D, et al. Clinical

and immunological features of severe and moderate

coronavirus disease 2019. J Clin Invest, 2020; 130(5):

-2629.

Henry BM, de Oliveira MHS, Benoit S, Plebani M,

Lippi G. Hematologic, biochemical and immune

biomarker abnormalities associated with severe

illness and mortality in coronavirus disease 2019

(COVID-19): A meta-analysis. Clin Chem Lab Med,

; 58(7): 1021-1028

Frater JL, Zini G, d'Onofrio G, Rogers HJ. COVID-19

and the clinical hematology laboratory. Int J Lab

Hematol, 2020; 42(1): 11–18.

Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang

MMG, et al. Diagnosis of SARS-CoV-2 infection and

COVID-19: Accuracy of signs and symptoms;

molecular, antigen, and antibody tests; and routine

laboratory markers (Protocol). Cochrane Database of

Systematic Reviews, 2020; 4: Art. No. CD013596.

Chan AS, Rout A. Use of neutrophil-to-lymphocyte

and platelet-to- lymphocyte ratios in COVID-19. J Clin

Med Res, 2020; 12(7): 448-453.

Ustundag Y, Huysal K, Gecgel SK, Unal D.

Relationship between C-reactive protein, systemic

immune- inflammation index, and routine

hemogram-related inflammatory markers in

low-grade inflammation. Int J Med Biochem, 2018;

(1): 24-8.

Lagunas-Alvarado M, Mijangos-Huesca FJ,

Ter´an-Gonz´alez JO, Lagunas-Alvarado MG,

Martinez-Zavala M, Reyes Franco I, et al. Systemic

immune inflammatory index in sepsis. Med. Int, 2017;

(3): 303–309.

Zhang B, Zhou X, Qiu Y, Feng F, Feng J, et al. Clinical

characteristics of 82 death cases with COVID-19. PLoS

One, 2020; 15(7): e0235458.

Ferrari D, Motta, A, Strollo A, Banfi G, Locatelli M.

Routine blood tests as a potential diagnostic tool for

COVID-19. Clin Chem Lab Med, 2020; 58(7): 1095-99.

Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, et al. Clinical

features and chest CT manifestations of Coronavirus

Disease 2019 (COVID-19) in a single-center study in

Shangai, China. Cardiopulmunary Imaging, 2020;

: 1–6.

Fei Y, Wang X, Zhang H, Huang M, Chen X, Zhang C. Reference intervals of systemic immune-inflammation

index, neutrophil to lymphocyte ratio, platelet to

lymphocyte ratio, mean platelet volume to platelet

ratio, mean platelet volume, and red blood cell

distribution width-standard deviation in healthy Han

adults in Wuhan region in central China. Scandinavian

Journal of Clinical and Laboratory Investigation, 2020;

(6): 500-507.

Ruta VM, Man AM, Alexescu TG, Motoc NS, Tamura S,

et al. Neutrophil-to-lymphocyte ratio and systemic

immune-inflammation index—biomarkers in

interstitial lung disease. Medicine, 2020; 56: 381.

Wang Y, Li Y, Chen P, Xu W, Wu Y, Che G.

Prognostic value of the pretreatment Systemic

Immune-Inflammation Index (SII) in patients with

non-small cell lung cancer: A meta-analysis. Ann.

Transl. Med, 2019; 7: 10.

Patra M, Mahapatra C, Kar PK, Prusty N, Nath PK.

Multilineage hematologic pattern involvement in

COVID-19 evaluation from peripheral blood elements.

National Journal of Laboratory Medicine, 2021; 10(2):

PO09-PO13.

Dong M, Shi Y, Yang J, Zhou Q, Lian Y, et al. Prognostic

and clinicopathological significance of systemic

immune inflammation index in colorectal cancer: A

meta-analysis. Ther Adv Med Oncol, 2020; 12: 1–14.

Li H, Huang J, Pan W, Zhang C, Chang X, Yang B.

Systemic immune-inflammatory index predicts

prognosis of patients with COVID-19: A retrospective

study. Research Square, 2020; 1-37.

Luo X, Zhou W, Yan X, Guo T, Wang B, et al. Prognostic

value of C-reactive protein in patients with

Coronavirus 2019. Clin Infect Dis, 2020; 23: ciaa641.

Xue G, Gan X, Wu Z, Xie D, Xiong Y, et al. Novel

serological biomarkers for inflammation in predicting

disease severity in patients with COVID-19.

International Immunopharmacology, 2020; 89: 107065.




DOI: http://dx.doi.org/10.24293/ijcpml.v27i3.1707

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.